



6 May 2021

## **Halucenex Life Sciences Inc. secures agreement with new contract testing laboratory R&D partner Nucro-Technics**

### **Highlights:**

- **Agreement with Nucro-Technics to test the stability and shelf life of psilocybin liquid formulations for use in its phase II clinical trial**
- **Nucro-Technics is a leading Canadian pharmaceutical contract research organisation**
- **The group has been in operation for nearly 50 years, employs over 170 scientific support personnel and has a 60,000 sq. ft. facility in Toronto**
- **Phase II clinical trial will test the efficacy of psilocybin on the treatment of Treatment Resistant Post Traumatic Stress Disorder (PTSD)**
- **Agreement adds to list of Halucenex's leading industry partnerships**

**Creso Pharma Limited (ASX: CPH, FRA:1X8) ('Creso Pharma' or 'the Company')** is pleased to advise that target acquisition company Halucenex Life Sciences Inc. ("Halucenex") has signed an agreement with leading pharmaceutical contract research organisation Nucro-Technics to provide microbiology and chemistry test work for a salient delivery solution using synthetic psilocybin which will be used in upcoming clinical trial submissions ("Agreement").

Nucro-Technics is a Canadian company that partners with pharmaceutical, biologic and medical device companies globally to assist with R&D initiatives. The group has been in operation for nearly 50 years and employ over 170 scientific support personnel that operate a state-of-the-art 60,000 square foot facility in Toronto. Nucro-Technics is inspected by and in compliance with the US FDA and Health Canada, amongst other regulatory bodies.

Under the Agreement, Halucenex will work with Nucro-Technics to test the stability and shelf life of psilocybin liquid formulations for use in its phase II clinical trial. Halucenex will have access to a GMP certified lab to formulate and test the bioavailability of its synthetic psilocybin compound, the ability to handle control substances for formulations of current delivery solutions and potential future methods that may have a faster onset. The agreement will also provide the Company with the ability to develop and validate methods for potency, component identification and microbiology for botanical psilocybe mushrooms grown in the future at Halucenex. Nucro-Technics will be paid a fixed fee of CAD\$38,202 for the scope of services defined under the Agreement. Halucenex has the right to cancel the Agreement at any time upon written notice and payment of costs plus a fair and reasonable cancellation fee to be agreed by the parties.

As previously advised (refer ASX announcement: 15 March 2021) Halucenex is pending receipt of a Controlled Drugs and Substances Dealer's License (Dealer's License) from Health Canada.

Upon receipt of the Dealers License, Halucenex intends to apply for Clinical Trial Authorisation and commence a Phase II clinical trial, which will research the efficacy of psilocybin on the treatment of Treatment Resistant Post Traumatic Stress Disorder (PTSD).



The proposed phase II clinical trial is designed to be a single-arm, open-lab trial that will ultimately determine the feasibility of future trials of psilocybin in this indication. 18 to 20 individuals (over 18 years old) that suffer from Treatment Resistant PTSD will be enrolled in the trial.

Halucenex also has an affiliation with Veterans Affairs Canada via strategic adviser David Fraser, which will expedite revenue generation through sales into a market with significant demand and government backing. The trial is expected to commence in Q3 2021, subject to receipt of all necessary regulatory approvals.

**Commentary:**

**Halucenex Founder and CEO Mr Bill Fleming said:** *“Nucro-Technics have a defined area of expertise that will be instrumental in the preparations for our upcoming phase II clinical trial. Further, the group compliments our existing suite of industry leading partners that will assist Halucenex in becoming a leading researcher and provider of Psychedelic-Assisted Psychotherapy.”*

*“Management are continuing to work diligently to progress trial initiatives and we expect to achieve a number of regulatory milestones in the near term. The receipt of a Dealer’s License from Health Canada will provide us with another considerable competitive advantage in what is becoming a large and lucrative vertical.”*

**Non-executive Chairman Adam Blumenthal said:** *“The continued progress Halucenex is making is very pleasing and we anticipate the acquisition and near term milestones will unlock significant value for shareholders.”*

*“Alongside Halucenex, the Board and management team are continuing to work through strategies to drive growth in key markets including the North America, Europe and Australia. Demand for our products continue to increase and we look forward to updating shareholder on developments shortly.”*

**-Ends-**

**Authority and Contact Details**

This announcement has been authorised for release by the Board of Creso Pharma Limited.

For further information, please contact:

**Investor Enquiries**

EverBlu Capital

E: [info@everblucapital.com](mailto:info@everblucapital.com)

P: +61 2 8249 0000

**Released through:**

Ben Jarvis, Six Degrees Investor Relations: Ph: +61 (0) 413 150 448



## About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: [www.cresopharma.com](http://www.cresopharma.com)

## About Nucro-Technics

NUCRO-TECHNICS is a Pharmaceutical Contract Research Organization (CRO) that is a partner to pharmaceutical, biologic, and medical device companies located all over the world. In business since 1970, we are located in a state-of-the-art 60,000 square foot facility a short drive from downtown Toronto, Canada. Employing a staff of more than 170 scientific support personnel, our analysts have more than 4,000 years of combined experience with significant expertise in testing both large molecule and small molecule compounds. As an organization Nucro-Technics is inspected by, and is in compliance with:

- The US FDA (Food and Drug Administration);
- Health Canada;
- The Standards Council of Canada to the OECD GLP Standard; and
- ISO 9001:2015.

## Forward Looking statements

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.